Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus has been building novel biological foundation models and agentic workflows by leveraging its more than 500 petabytes of rich, molecularly grounded data—more than 45 million total de-identified patient journeys, 1.5 million with sequenced data, and over 400,000 records in cancer with full genomic, transcriptomic, imaging, and clinical data. These efforts transform this data into unified patient representations, unlocking actionable insights to speed precision medicine efforts in both the clinic and drug development.
Tempus’ latest multimodal, transformer-based model was trained on 2.5 million longitudinal records encapsulating more than 250 million pages of clinical notes, 450,000 digitized medical images, and 500,000 genomic and transcriptomic sequences. By aggregating modalities derived from billion-parameter foundation models, it is designed to address thousands of prediction objectives anchored in overall survival (OS) and progression-free survival (PFS), without requiring additional data or model fine-tuning. This architecture significantly reduces the time and data required to produce hundreds of clinically relevant insights for clinical trial design, patient risk prediction, and novel multimodal diagnostics.
